Mass Spectrometry-Based Analysis of Serum N‑Glycosylation Changes in Patients with Parkinson’s Disease
journal contributionposted on 2022-05-31, 20:11 authored by Mingming Xu, Hong Jin, Zhen Wu, Ying Han, Jing Chen, Chengjie Mao, Piliang Hao, Xumin Zhang, Chun-Feng Liu, Shuang Yang
It is urgently needed to find reliable biofluid biomarkers for early diagnosis of Parkinson’s disease in order to achieve better treatment. Promising biomarkers can be found in Parkinson’s disease-related glycoproteins as aberrant protein glycosylation plays an important role in disease progression. However, current information on serum N-glycoproteomic changes in Parkinson’s disease is still limited. Here, we used glycoproteomics methods, which combine the solid-phase chemoenzymatic method, lectin affinity chromatography, and hydrophilic interaction chromatography with high-resolution mass spectrometry, to analyze the glycans, glycosites, and intact glycopeptides of serum. Increased abundance of glycans containing core fucose, sialic acid, and bisecting N-acetyl glucosamine was detected at the overall glycan level and also at specific glycosites of glycopeptides. Five Parkinson’s disease-associated proteins with this type of N-glycosylation changes were also identified. We propose that the revealed site-specific N-glycosylation changes in serum can be potential biomarkers for Parkinson’s disease.
used glycoproteomics methodsphase chemoenzymatic methodoverall glycan levellectin affinity chromatographyhydrophilic interaction chromatographyachieve better treatment>- acetyl glucosamineresolution mass spectrometryfive parkinson ’parkinson ’mass spectrometryurgently neededstill limitedsialic acidrevealed siterelated glycoproteinspromising biomarkerspotential biomarkersincreased abundanceimportant roleglycosylation changesglycoproteomic changesearly diagnosiscurrent informationbased analysisassociated proteins